- Home
- GLPG vs IBRX Comparison
GLPG vs IBRX Comparison
Compare GLPG & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- IBRX
- Stock Information
- Founded
- GLPG 1999
- IBRX 2014
- Country
- GLPG Belgium
- IBRX United States
- Employees
- GLPG N/A
- IBRX N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GLPG Health Care
- IBRX Health Care
- Exchange
- GLPG Nasdaq
- IBRX Nasdaq
- Market Cap
- GLPG 2.1B
- IBRX 2.3B
- IPO Year
- GLPG 2005
- IBRX N/A
- Fundamental
- Price
- GLPG $33.24
- IBRX $2.85
- Analyst Decision
- GLPG Sell
- IBRX Strong Buy
- Analyst Count
- GLPG 3
- IBRX 6
- Target Price
- GLPG $26.00
- IBRX $9.83
- AVG Volume (30 Days)
- GLPG 162.5K
- IBRX 10.0M
- Earning Date
- GLPG 10-29-2025
- IBRX 11-11-2025
- Dividend Yield
- GLPG N/A
- IBRX N/A
- EPS Growth
- GLPG N/A
- IBRX N/A
- EPS
- GLPG N/A
- IBRX N/A
- Revenue
- GLPG $323,674,692.00
- IBRX $56,600,000.00
- Revenue This Year
- GLPG $1.77
- IBRX $629.94
- Revenue Next Year
- GLPG N/A
- IBRX $109.91
- P/E Ratio
- GLPG N/A
- IBRX N/A
- Revenue Growth
- GLPG 5.43
- IBRX 4227.22
- 52 Week Low
- GLPG $22.36
- IBRX $1.83
- 52 Week High
- GLPG $33.86
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- GLPG 58.22
- IBRX 68.32
- Support Level
- GLPG $31.49
- IBRX $2.32
- Resistance Level
- GLPG $33.63
- IBRX $2.67
- Average True Range (ATR)
- GLPG 0.68
- IBRX 0.14
- MACD
- GLPG 0.01
- IBRX 0.06
- Stochastic Oscillator
- GLPG 85.82
- IBRX 82.35
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.